vimarsana.com

Page 130 - ஆரோக்கியம் பராமரிப்பு ஆம்ப் மருத்துவமனைகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Leap Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results

Leap Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results News provided by Share this article Share this article CAMBRIDGE, Mass., March 12, 2021 /PRNewswire/  Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2020. 2020 Leap Highlights: Signed agreement with BeiGene, Ltd. for rights to Leap s anti-DKK1 antibody, DKN-01, in Asia (excluding Japan), Australia and New Zealand Completed a $51.75 million public offering of common stock and pre-funded warrants to purchase common stock Presented updated data from study of DKN-01 plus pembrolizumab in esophagogastric (EGC) cancer demonstrating positive outcomes in DKK1-high patients

World Epilepsy Drugs Market and Global Epilepsy Drugs Competitor Market Share Scenario 2020-2027

Share this article Share this article ResearchAndMarkets.com s offering. Amid the COVID-19 crisis, the global market for Epilepsy Drugs estimated at US$ 4.6 Billion in the year 2020, is projected to reach a revised size of US$ 5.8 Billion by 2027, growing at a CAGR of 3.3% over the analysis period 2020-2027. First Generation, one of the segments analyzed in the report, is projected to record a 2.5% CAGR and reach US$ 1.4 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Second Generation segment is readjusted to a revised 3.2% CAGR for the next 7-year period.

ECEC Applauds Passage of the American Rescue Plan

ECEC Applauds Passage of the American Rescue Plan News provided by Share this article Share this article WASHINGTON, March 12, 2021 /PRNewswire/  Yesterday, President Biden signed the American Rescue Plan Act of 2021 (ARPA) into law. ARPA is a sweeping COVID-19 pandemic relief package providing over $42 billion in direct relief funds to the child care industry, including $24 billion to stand up a child care stabilization fund, $15 billion through the Child Care and Development Block Grant (CCDBG) program and $3.5 billion in mandatory funding through the Child Care Entitlement to the States. In addition to direct relief, the package also includes $1 billion for Head Start programs and robust one-year expansions of three critical tax relief programs the Child Tax Credit, the Child and Dependent Care Tax Credit, and Dependent Care FSAs.

One Year Later, Pandemic Fear Erased at Chelsea Communities

One Year Later, Pandemic Fear Erased at Chelsea Communities News provided by Share this article FANWOOD, N.J., March 12, 2021 /PRNewswire/  What a difference a year makes! It was March 12, 2020, when COVID-19 arrived and our assisted living communities locked down. Visitation was stopped, residents had to be isolated in their apartments, marketing was suspended. Supporting the communities through the COVID-19 pandemic became a 24/7 focus. A resident of the Chelsea at Marlboro receives her first shot. The pandemic has impacted all of us residents, staff, families and our health care partners.  And although we deeply feel the pain of every loss in our communities, there is a sense of pride in knowing Chelsea did push forward through a most difficult time with a deliberate, professional and compassionate focus to minimize the spread of this infection and utilize emerging technologies and treatments to provide state of the art care.

Global Pharma and Biotech Discovery Stage Partnering Terms and Agreements Directory 2014-2021

Share this article Share this article ResearchAndMarkets.com s offering. The report provides a detailed understanding and analysis of how, why and on what terms companies enter discovery stage partnering deals. These deals are discovery stage whereby the licensee obtains a right or an option right to license the licensors product or technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.